Novavax, Inc.

Who owns Novavax?
Novavax, Inc. is a publicly traded company listed on the Nasdaq stock exchange under ticker NVAX. The company has a dispersed shareholder base with no single controlling shareholder. Institutional investors, including Vanguard Group, BlackRock, and State Street Global Advisors, hold the majority of shares. The company has also received significant government funding from the US government through Operation Warp Speed and from CEPI for vaccine development.

Is Novavax publicly traded?
Yes, Novavax, Inc. is publicly traded on the Nasdaq stock exchange under ticker NVAX. The company went public in 1995 and has been listed on Nasdaq since then. The stock experienced significant volatility during the COVID-19 pandemic, reaching highs in 2021 before declining as the vaccine market contracted. The stock has partially recovered following the Sanofi and Pfizer licensing deals in 2024 and 2025.

What is Novavax's revenue?
Novavax reported FY2025 revenue of $634 million. Revenue is generated through COVID-19 vaccine sales, Sanofi partnership payments (up to $1.2 billion in upfront and milestones plus royalties), Pfizer licensing payments (up to $350 million in milestones plus royalties), and government contracts. The company's revenue model has shifted from direct vaccine sales toward partnership and licensing revenue, which provides more predictable income but limits upside from direct product sales.

What is Matrix-M adjuvant technology?
Matrix-M is Novavax's proprietary adjuvant technology, derived from saponin compounds found in the bark of the Quillaja saponaria tree. The adjuvant enhances immune response by stimulating antigen-presenting cells, allowing lower doses of vaccine antigen to achieve strong immune responses. Matrix-M is the core of Novavax's value proposition, as demonstrated by licensing deals with Sanofi (May 2024, up to $1.2 billion plus royalties) and Pfizer (January 2025, up to $350 million in milestones plus royalties).

What is Novavax's COVID-19 vaccine?
Novavax's COVID-19 vaccine is a protein-based vaccine using recombinant spike protein nanoparticles combined with the Matrix-M adjuvant. It is marketed as Nuvaxovid internationally and as Novavax COVID-19 Vaccine, Adjuvanted in the United States. The FDA granted emergency use authorization in July 2022 and full approval in July 2025 for individuals 12 and older. The vaccine offers an alternative to mRNA vaccines for consumers who prefer protein-based vaccine technology.

Who are Novavax's key partners?
Novavax's key partners are Sanofi and Pfizer. Sanofi signed a strategic partnership in May 2024 worth up to $1.2 billion in upfront and milestone payments plus royalties, licensing Matrix-M technology and assuming commercialization of Novavax's COVID-19 vaccine in certain markets. Pfizer signed a licensing agreement in January 2025 worth up to $350 million in milestones plus royalties for use of Matrix-M in Pfizer's vaccine products. Novavax also partners with the Serum Institute of India for manufacturing.

What is Novavax's pipeline?
Novavax's pipeline includes a COVID-19-influenza combination vaccine, standalone influenza vaccine, RSV vaccine, shingles vaccine, and C. diff vaccine. The COVID-influenza combination vaccine is the most advanced pipeline candidate and could offer convenience by protecting against both viruses in a single shot. The RSV, shingles, and C. diff candidates are in earlier stages of development. All pipeline candidates use the Matrix-M adjuvant platform.

Novavax was founded in 1987 in Gaithersburg, Maryland. The company focused on vaccine development using recombinant protein technology from its founding. Novavax went public in 1995, raising capital for research and development. In its early years, the company developed vaccine candidates for various infectious diseases including influenza, respiratory syncytial virus (RSV), and Ebola.

In the 2000s and 2010s, Novavax advanced its vaccine pipeline through clinical trials. The company developed its proprietary Matrix-M adjuvant technology, derived from saponin compounds found in the Quillaja saponaria tree bark. Matrix-M enhances immune response by stimulating antigen-presenting cells, allowing lower doses of antigen to achieve strong immune responses. The company received funding from government agencies including the National Institutes of Health and the Biomedical Advanced Research and Development Authority (BARDA) to support vaccine development.

During the COVID-19 pandemic, Novavax accelerated development of its COVID-19 vaccine, NVX-CoV2373 (later branded Nuvaxovid). The company received $1.6 billion in funding from the US government through Operation Warp Speed and additional funding from CEPI. Novavax completed clinical trials demonstrating efficacy and received emergency use authorization in multiple countries starting in 2021 and 2022. The FDA granted emergency use authorization for the Novavax COVID-19 Vaccine, Adjuvanted in July 2022 for individuals 18 and older, and full approval in July 2025 for individuals 12 and older.

The COVID-19 vaccine became Novavax's first commercial product, generating significant revenue in 2022 and 2023. However, the company faced challenges with manufacturing scale-up, regulatory approval timelines, and competition from mRNA vaccines from Pfizer-BioNTech and Moderna, which reached the market earlier and captured the majority of market share.

In May 2024, Novavax signed a transformative strategic partnership with Sanofi. Under the agreement, Sanofi acquired a non-exclusive license to use Matrix-M adjuvant technology in its own vaccine products and assumed responsibility for commercializing Novavax's COVID-19 vaccine in certain markets. The deal was worth up to $1.2 billion in upfront and milestone payments, plus royalties on Sanofi's products using Matrix-M. This partnership provided Novavax with a sustainable revenue stream beyond its own COVID-19 vaccine sales.

In January 2025, Novavax signed a licensing agreement with Pfizer for Matrix-M adjuvant technology. Pfizer paid an undisclosed upfront fee and agreed to up to $350 million in milestone payments plus royalties for use of Matrix-M in Pfizer's vaccine products. This second major licensing deal validated the platform value of Novavax's adjuvant technology beyond COVID-19.

For FY2025, Novavax reported revenue of $634 million, driven by Sanofi partnership payments, COVID-19 vaccine sales, and milestone payments. The company's revenue model has shifted from direct vaccine sales toward partnership and licensing revenue, which provides more predictable and sustainable income.

Novavax has not published independently verified sustainability targets through the Science Based Targets Initiative. The company does not hold B Corp certification. As a biotechnology company, Novavax's environmental impact is primarily related to laboratory operations, clinical trial logistics, and manufacturing through contract partners. The company does not publish a standalone ESG report, and sustainability disclosures are limited to what is included in its 10-K filings with the SEC.

Novavax faced significant manufacturing and regulatory challenges during the COVID-19 pandemic. The company struggled to scale up manufacturing to meet global demand, and regulatory approvals in the US and Europe were delayed compared to mRNA vaccines. The FDA's emergency use authorization came in July 2022, more than a year after Pfizer-BioNTech and Moderna received their authorizations. This delay allowed mRNA vaccines to capture the majority of the market before Novavax's product was available.

The company received scrutiny over its going concern status. In 2023, Novavax disclosed substantial doubt about its ability to continue as a going concern, given declining COVID-19 vaccine demand and limited cash reserves. The stock price declined significantly from its pandemic-era highs. The Sanofi partnership in 2024 alleviated these concerns, but the episode highlighted the vulnerability of a company dependent on a single product in a rapidly changing market.

Novavax has also faced questions about the durability of its COVID-19 vaccine's protection compared to mRNA vaccines. Protein-based vaccines may offer different immune response profiles than mRNA vaccines, but direct comparative data has been limited. The company has conducted additional studies to demonstrate the vaccine's efficacy against emerging variants.